Skip to content

Magy Abdelwahab is a Professor of Pediatrics and Pediatric hematology (expert in disorders of bleeding and thrombosis) at Cairo University Pediatric Hospital, the biggest tertiary Pediatric Hospital in Egypt and one of the biggest in the Middle East. She is an expert in Gaucher disease (especially nGD) and senior consultant of Gaucher disease clinic.  She qualified in Medicine, did her MSc and PhD in Pediatrics at Cairo University. She trained in Egypt and the UK in Pediatrics, Pediatric hematology and Neurology, LSD unit Royal Free hospital, London and worked in Royal Hospital for Sick Children in Glasgow and Edinburgh, Scotland. She is managing a big diverse cohort of more than 100 patients and is an active participating member of the Egyptian American Gaucher disease committee, member of International Working Group of Gaucher Disease (IWGGD) and of SAC( Scientific Advisory Committee) of IGA( International Gaucher Alliance. She made new observations regarding neurological and non-neurological manifestations of type 3 Gaucher disease and is involved in several research projects. She is an   invited guest speaker in many international meetings and conferences. She participated in writing and reviewing Gaucher disease booklets mainly addressing type 3 GD. Her last publications are entitled Throwing a spotlight on under-recognized manifestations of Gaucher disease: Pulmonary involvement, lymphadenopathy and Gaucheroma and “Investigation of a dysmorphic facial phenotype in patients with Gaucher disease types 2 and 3.

Statement for promoting GARDIAN: GARDIAN …. You will help yourself and help other GD patients and their families and the whole GD community BY sharing your data, your experience and the story of your life, its impact on your daily life as well as the different stages of your life and the challenges you went through and how you overcame them

So, contributing to our better understanding of the disease and improving on our management plans, coming up with better treatments, better end points for clinical trials and hopefully in due time CURING this disease

You get to document your data, what you feel, making physicians pay attention to overlooked manifestations of the disease and their impact